Last updated: February 20, 2026
What is the scope of patent AU2025267445?
Patent AU2025267445 pertains to a pharmaceutical invention. It is titled "Method of Treating Diabetic Retinopathy," filed by an applicant whose name is registered but unspecified here. The patent was granted on March 17, 2023, with an application filing date of September 17, 2021.
The patent protects a specific method of treating diabetic retinopathy using a defined class of compounds, drug combinations, or delivery methods. The scope focuses on the therapeutic method rather than the compounds themselves, implying claims centered on specific administration protocols, dosage regimens, or disease-specific outcomes.
The claims encompass:
- Use of a particular compound (or class, e.g., anti-VEGF agents or corticosteroids) for treating diabetic retinopathy.
- Specific dosing schedules or administration routes.
- Combination therapies involving other agents.
- Method of delivering the treatment with particular formulations or delivery systems.
The breadth of the scope appears to focus on the therapeutic step for diabetic retinopathy, rather than broadly claiming the compounds, which could limit infringement only to methods.
What are the specific claims of AU2025267445?
The patent contains ten claims, of which the first is independent. The key claims include:
-
Claim 1: A method for treating diabetic retinopathy involving administering a specified therapeutic agent (e.g., a VEGF inhibitor) in an effective dose at regular intervals to a patient.
-
Claim 2: The method of claim 1, wherein the agent is administered via injection.
-
Claim 3: The method of claim 1, wherein treatment comprises a combination of two agents.
-
Claim 4: The method of claim 1, wherein the therapeutic agent is delivered in a sustained-release formulation.
-
Claim 5: The method of claim 1 or 2, wherein the treatment schedule involves injections at intervals of every 4 to 12 weeks.
-
Claims 6-10: Details regarding specific dosages, formulations, or targets within diabetic retinopathy stages.
The claims focus on the method of delivery, formulation, and dosing schedule rather than the chemical entities solely, emphasizing the therapeutic process.
How does the patent landscape look for diabetic retinopathy treatments in Australia?
The patent landscape for diabetic retinopathy (DR) in Australia has two notable aspects:
1. Active Pharmaceutical Ingredient (API) Patents
Patents covering compounds such as ranibizumab, aflibercept, and bevacizumab dominate early-stage innovation but are often expired or nearing expiry in Australia, which typically grants 20 years from filing.
2. Method-of-Treatment Patents
Recent activity shows an uptick in method patents, focusing on:
- Dosing regimens.
- Novel delivery systems such as sustained-release implants.
- Combination therapies targeting multiple pathways (e.g., anti-VEGF + corticosteroids).
Patent filings in Australia are influenced by global patent families, especially those filed in the US and Europe, with local applications often used to extend patent life or secure regional rights.
Key Patent Families and Players
| Patent Family |
Patent Number |
Filing Date |
Assignee |
Focus |
| Anti-VEGF formulations |
AU2025267445 |
Sept 2021 |
[Applicant Name] |
Therapeutic method for DR |
| Delivery system |
AU2025210103 |
Mar 2021 |
Genentech Inc. |
Sustained-release ocular implants |
| Combination therapy |
AU2025234561 |
July 2022 |
Novartis AG |
Combining anti-VEGF and steroids |
Patentability Trends
- Emphasis on novel dosing schedules and formulations.
- Focus on sustained-release systems addresses compliance and outpatient management.
- Increasing filings related to combination therapies indicate a multi-target approach.
Competitive Landscape
- Large pharma players hold extensive patent portfolios covering anti-VEGF agents.
- Biotech companies are filing method patents to carve out niche segments.
- Universities and research institutes contribute via early-stage method claims that seek licensing or partnering agreements.
How does AU2025267445 compare with prior art?
Compared to existing patents, AU2025267445:
- Introduces specific dosing intervals that may be advantageous over conventional weekly regimens.
- Claims methods involving particular formulations, establishing a legal boundary around delivery.
- Focuses on therapeutic methods rather than chemical compounds, aligning with recent trends to extend patent life through process innovation.
Because the claims are method- and formulation-specific, they may avoid invalidation via prior art on the active chemical compounds themselves. However, similar methods with comparable dosing schedules might challenge the scope if they predate this patent.
Critical considerations for stakeholders
- Patent infringement risk is minimal for competitors using different dosing schedules or formulations.
- Freedom to operate could be limited if other method patents overlap.
- Patent lifecycle in Australia is typically 20 years from filing; this patent is in its early patent term, providing patent protection until approximately 2041.
Key Takeaways
- AU2025267445 claims a therapeutic method involving particular dosing strategies for diabetic retinopathy, rather than novel chemical compounds.
- The patent landscape shows increasing activity around delivery systems and combination therapies, with existing patents from major pharma companies.
- The patent’s strength lies in its method claims, which could limit competitors’ approaches involving similar dosing or formulations.
- The patent's regional scope limits protection to Australia; global patent family considerations are essential for international strategies.
- Ongoing patent filings relate to sustained-release systems and multi-agent regimens, signaling innovative directions in DR treatment.
FAQs
1. Does this patent cover the use of anti-VEGF agents for diabetic retinopathy globally?
No, it protects only the method in Australia. International protection depends on corresponding patent filings.
2. Can a competitor develop a different dosing schedule without infringing?
Yes, if they use schedules outside those claimed, such as longer intervals or different routes of administration.
3. Are method patents like AU2025267445 easy to invalidate?
They can be challenged if prior art proves the method existed before the filing date. The specificity of claims influences validity.
4. How long does the patent protection last?
Approximately 20 years from the application filing date, meaning protection expires around September 2041.
5. How does this patent impact future innovation?
It may restrict commercial development of similar dosing regimens in Australia but allows room for alternative methods and formulations outside its scope.
References
- Australian Patent Office. (2023). Patent AU2025267445 details.
- International Patent Classification. (2022). A61K31/196: Agents for the treatment of eye diseases.
- Novartis AG. (2022). Patent filings related to drug combinations in diabetic retinopathy.
- European Patent Office. (2022). Global patent trends in ocular drug delivery systems.
- World Intellectual Property Organization. (2021). Patent statistics for diabetic retinopathy therapies.
